 ROCKVILLE, Md., Oct. 04, 2021 GLOBE NEWSWIRE -- OpGen, Inc. Nasdaq: OPGN, OpGen, a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that total preliminary unaudited revenue for the third quarter of 2021 was approximately 1.2 million, up from 1.1 million in the third quarter of 2020. Cash as of September 30, 2021 was approximately 25.4 million, an increase from the 13.4 million as of December 31, 2020. 